Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Genetron Holdings Limited
  6. News
  7. Summary
    GTH   US37186H1005

GENETRON HOLDINGS LIMITED

(GTH)
  Report
Delayed Nasdaq  -  05/24 04:00:00 pm EDT
1.370 USD   -4.86%
05/23Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022
GL
05/23Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Investor Call on June 2, 2022
GL
04/21BTIG Adjusts Genetron Holdings' Price Target to $10 From $17, Keeps Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Genetron Holdings Limited Reiterates Full Year 2021 Revenue Guidance

01/10/2022 | 06:00am EDT
share with twitter
share with LinkedIn
share with facebook

Genetron Holdings Limited reiterated its full year 2021 revenue guidance. The Company expects full year 2021 revenue to be around RMB 530 million, representing approximately 25% growth over the Company’s full year 2020 revenue.


© S&P Capital IQ 2022
All news about GENETRON HOLDINGS LIMITED
05/23Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Inv..
GL
05/23Genetron Health to Announce First Quarter 2022 Unaudited Financial Results and Host Inv..
GL
04/21BTIG Adjusts Genetron Holdings' Price Target to $10 From $17, Keeps Buy Rating
MT
04/19Genetron Obtains CE Mark for Human B Lymphocyte Minimal Residual Disease Detection Kit
MT
04/19Genetron Health Receives CE Mark for Human B Lymphocyte Minimal Residual Disease Detect..
AQ
04/08Genetron Health Presents 17 New Research Results at American Association for Cancer Res..
GL
04/07Publication in Clinical and Translational Medicine Demonstrates Mutation Capsule™..
GL
04/07Publication in Clinical and Translational Medicine Demonstrates Mutation Capsule™..
GL
03/29TRANSCRIPT : Genetron Holdings Limited, Q4 2021 Earnings Call, Mar 29, 2022
CI
03/29GENETRON : Health Announces Unaudited Fourth Quarter and Full Year 2021 Financial Results ..
PU
More news
Analyst Recommendations on GENETRON HOLDINGS LIMITED
More recommendations
Financials (USD)
Sales 2022 97,3 M - -
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -10,1x
Yield 2022 -
Capitalization 124 M 124 M -
Capi. / Sales 2022 1,28x
Capi. / Sales 2023 0,98x
Nbr of Employees 1 154
Free-Float 91,0%
Chart GENETRON HOLDINGS LIMITED
Duration : Period :
Genetron Holdings Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENETRON HOLDINGS LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,37 $
Average target price 4,76 $
Spread / Average Target 247%
EPS Revisions
Managers and Directors
Si Zhen Wang Chairman & Chief Executive Officer
Ce Xu Chief Financial Officer
Hai Yan Director & Chief Scientific Officer
Yu Chen Jiao Chief Technology Officer & Director
Yun Fu Hu Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
GENETRON HOLDINGS LIMITED-77.54%124
MODERNA, INC.-48.00%52 528
LONZA GROUP AG-27.13%42 896
IQVIA HOLDINGS INC.-28.41%38 232
SEAGEN INC.-13.67%24 569
ICON PUBLIC LIMITED COMPANY-30.17%17 581